ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
CCK-1R-selective and non-selective cholecystokinin antagonists, lorglumide, and proglumide increased toxicity of carboplatin to granulocyte-macrophage progenitor cells (CFU-GM) of bone marrow of rats.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Cholecystokinin antagonists are investigated to use against pancreas and hepatocarcinomas, the risks of which are higher in obesity with poorer prognosis than in nonobese patients. We studied their effects on granulocyte-macrophage progenitor (CFU-GM), the key target of myelotoxicity of chemotherapy. Colony formation of CFU-GM was studied after the same molar doses of proglumide or lorglumide (iv, 5 days). Direct toxicity of carboplatin was determined against CFU-GM progenitors of LETO rats pre-treated with proglumide or lorglumide and against progenitors of their obese counterparts OLETF rats. Cholecystokinin receptors were studied by qPCR. Proglumide and lorglumide damaged granulopoiesis in vivo and inhibited CFU-GM of LETO rats dose-dependently in vitro. The CCK-1R-selective lorglumide caused more powerful inhibition than non-selective proglumide both in vitro and in vivo. Increased carboplatin toxicity was measured in vitro against CFU-GM obtained from either proglumide or lorglumide pre-treated rats. Carboplatin toxicity was significantly higher after lorglumide than proglumide pre-treatment, which confirmed protective effects via CCK-1R. Carboplatin damage was higher on CFU-GM progenitors of OLETF rats with CCK-1R deficiency than that of LETO rats. We detected both CCK-1R and CCK-2R in progenitors of bone marrow. Gene expressions of both CCK-Rs decreased after proglumide administration. Cholecystokinin antagonists affected granulopoiesis and sensitized granulocyte-macrophage progenitors against carboplatin toxicity presumably by inhibition of the protective role of cholecystokinin via CCK-1R. It is the first proof about the presence and possible role of CCK-1 receptor in granulopoiesis. These might have value if CCK antagonists are used in malignancies, obesity, or with immunosuppressive therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.